Investment Rational

Vidac is a clinical-stage oncology company developing novel drugs targeting metabolic immuno-oncology processes in cancer. Lead product, VDA-1102, is in Phase 2 for actinic keratosis (AK; early cutaneous squamous cell carcinoma) with data in mid-2017. Phase 3 is to start in 1H 2018. VDA-1102 is also being developed for a variety of solid tumors.

Business Strategy

AK is a prevalent early-stage of skin cancer (60M people in US; rage-related incidence-rate; $7B market size). Vidac is developing VDA-1102 ointment for AK under an FDA IND. Following Phase 2 POC we plan to develop the drug to an NDA and to co-market it. A second product, injectable VDA-1102 for solid tumors, will be developed through POC.

Core Technology

Cancer cells, and activated immune cells, undergo metabolic reprogramming from OXPHOS to glycolysis, expressing HK2 in that process. Vidac's novel small-molecule modulators of the VDAC/HK2 interface trigger apoptosis in cancer cells (without affecting the surrounding tissue) and stimulate the immune response. Vidac is developing a pipeline of highly selective, efficacious anti-cancer drugs (NCEs), using a precision medicine approach (HK2 levels).

Product Profile/Pipeline

VDA-1102 ointment is a topical treatment for AK. It is developed under an FDA IND (Phase 2 data in mid-2017; Phase 3 start in early-2018). NDA in expected in 2020. The drug is a first-in-class treatment with sales potential exceeding $1B. In addition, an injectable formulation of VDA-1102 for solid tumors is expected to begin clinical development in 2018.

What’s Next?

**VDA-1102 ointment**: Phase 2 topline data in mid-2017, followed by an End-of-Phase-2 meeting with FDA by YE 2017, and start of Phase 3 studies in 1H 2018.


**Financing**: Planned for 2H 2017.